APR TD012 is a clinical stage drug candidate for the treatment of wounds in Hailey Hailey Disease (HHD) patients. The product improves healing process thanks to its bioburden control and its anti-oxidant properties.
Oxidative stress has been demonstrated to play a specific role in the pathogenesis of HHD by regulating the expression of factors playing an important role in keratinocyte proliferation and differentiation.
Preliminary pre-clinical data suggest that our product could be able to shift the oxidation reduction (redox) balance, leading to a protective antioxidant response.
In addition, thanks to Hypochlorous acid (HClO) presence APR-TD012 could exert a strong antimicrobial activity inactivating one of the most common causes of skin infections in the HHD lesions, which is Staphylococcus aureus.